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one year post-discharge and compared between cohorts who receive and did not 
receive guideline recommended care using a probit regression model with instru-
mental variables. Results: One-fourth (29%) of the patients with COPD-related hos-
pitalizations/ED visits were identified as recipients of the guideline recommended 
care. Receiving guideline recommended care was associated with a reduction of 
4.4 percentage points in the probability of having subsequent COPD exacerbation 
requiring hospital admission/ED visits (p-value = 0.837). Analysis focusing on the 
follow up visit alone shows that having follow up visits were significantly associ-
ated (p-value = 0.018) with a reduction in the probability (32.8 percentage points) of 
having subsequent COPD exacerbation requiring hospital admission/ED visits, while 
the use of maintenance medication was associated with an increase in the prob-
ability (19.5 percentage points) of having subsequent COPD exacerbation requiring 
hospital admission/ED visits (p-value = 0.337). ConClusions: The use of guideline 
recommended care, especially in the use of follow up care, was significantly associ-
ated with the reduction in the probability of having subsequent COPD exacerbation 
requiring hospital admission/ED.
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objeCtives: Poor or non-adherence causes medical and psychosocial complica-
tions for patients and represents a considerable financial burden for health care 
systems worldwide. Medication adherence problems have not been routinely 
highly valued by health technology assessment (HTA) bodies in their evaluation 
assessments. In this study we assess the extent to which leading HTA bodies con-
sider the value of medication adherence in their reimbursement decision mak-
ing. Methods: Evaluation of published assessments made from 2010 to 2013 in 
five leading HTA bodies (Canadian Agency for Drugs and Technologies in Health 
(CADTH), the French National Authority for Health (HAS), England’s National 
Institute of Health and Care Excellence (NICE), the Australian Pharmaceutical 
Benefits Advisory Committee (PBAC) and the Scottish Medicines Consortium (SMC)) 
were reviewed for asthma, hypertension, diabetes, multiple sclerosis, psychological 
disorders and alcohol dependence. The primary outcome measure was to identify 
the number of assessments in which HTA bodies have considered adherence as 
a value message. Results: A total of 405 evaluation assessments were submit-
ted to HTA bodies for the above stated indications and timeframe. Out of these 
assessments, adherence was discussed in 65 (16.1%) of the assessments. However, 
adherence was not considered valuable for reimbursement decision making by HTA 
bodies in 19 of these 65 assessments. In the remaining 46 assessments, adherence 
was considered as a value message while making reimbursement decisions by the 
HTA bodies but it did not impact the final reimbursement decision in 79% of the 
instances. ConClusions: Leading HTA bodies have not considered medication 
adherence as a key metric in their reimbursement decision making.
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objeCtives: To analyze the out-of-pocket medical expenses of Basic Health 
Insurance participants between 2009 and 2012, and determine whether the indi-
vidual medical burden has been alleviated really in the health care reform from 
2009. Methods: This study used the data from the National Sample Survey on 
Medical Service Utilization of Basic Medical Insurance participants in 2009-2012.
This survey involved about 375 thousands in-patients with BMI from about 70 cit-
ies all over the country. All the actual claim data of medical expenses and medical 
care utilization from 2009 to 2012 were collected. Descriptive analysis was applied 
to the data and the related payment policies of BMI were reviewed. Results: 1) 
The total medical expenses burden of the BMI in-patients is keeping a high speed 
growth between 2009 and 2012, increased from about US$33 billion to about US$64.5 
billion (increased 25% per year). 2) The inpatient expenses presented a left skewed 
distribution. Over 55% of the expense burden came from 20% cases spending above 
US$3200. 3) The out-of-pocket rates of urban employee and residents were about 
29% and 49% respectively, and both of them presented a U-type pattern. The inpa-
tients spending below US$800 or above US$3200 had a higher burden. 4) The indi-
vidual medical burden presented an increase tendency with the increase of the 
hospital level. ConClusions: Generally, health insurance eased the economic bur-
den of inpatients and made out-of-pocket expense acceptable. But the individual 
burden for those inpatients with expenses above US$3200 had not been alleviated 
enough. New measures should be pursued to make further reduce, such as raising 
the reimbursement ceiling and providing new supplementary health insurance for 
severe illness. The increase speed of total medical burden should be controlled by 
lean formula management. The patients with commonly encountered illness should 
be guided to basic-level hospitals and supervision on medical service utilization 
should also be strengthened to control the irrational medical cost.
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objeCtives: To evaluate the perception of hospital pharmacists regarding quality of 
pharmaceutical care services in Khyber Pakhtunkhwa, Pakistan. Methods: Qualitative 
assessment was implemented. A semi-structured interview guide was developed 
and face to face interviews were conducted. Hospital pharmacists was interviewed 
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objeCtives: Although the evidence showed the risks of using sedative benzo-
diazepine (BZD) and long-terms use of non-BZD hypnotics (i.e., Z-drugs) among 
the elderly, it is still unavoidable to use these medications for the elderly to solve 
their insomnia problems. This study aimed to describe the utilization of hypnotic 
medications for outpatients in a 2000-bed medication center in Taiwan. Methods: 
We conducted a secondary data analysis using China Medical University Hospital 
(CMUH) in-house databases. From 2007 to 2013, those outpatients ever prescribed 
with, estazolam, lorazepam, diazepam, alprazolam, zolpidem and zopiclone were 
of interest. The prescription prevalence rates of these drugs, its average number of 
defined daily dose (DDD), prescriber specialties and demographic characteristics of 
patients were examined using descriptive analyses. Results: Those elder patients 
were prescribed with 133 ±158 DDD of Z-drugs in CMUH in 2007. 7.6% of them used 
Z-drugs exceed 365DDD within one year. In 2009, more than 40% of all 15,815 pre-
scriptions with BZD and Z-drug hypnotics were prescribed for patients aged 65 year 
or more. Of them, 44% of alprazolam, 51.1% of diazepam, 46% of estazolam, 41% of 
zolpidem, and 46% of zopiclone were prescribed for the elderly patients, respectively. 
In 2011, 40% of zolpidem users and 32% of zopiclone users were elderly. The top three 
prescribing specialists for Z-drugs were neurologist, cardiologist and psychiatrists 
in (accounted for 63.01% and 46.96% for zolpidem and zolpiclone, respectively). 
Of 12,982 patients being prescribed with 53,330 BZD and Z-drug prescriptions in 
2013, 76.9% were aged 65 year or more. The Z-drugs were still more common than 
BZD as a whole. ConClusions: While the elderly accounted for small proportion 
of medical care users, relatively larger proportions were prescribed with BZD and 
Z-drug hypnotics to manage their insomnia problems in CMUH across seven years. 
Further outcome assessments for such usage are necessary.
du4
Statin Medication uSe and tHe deVeloPMent of ProliferatiVe 
diabetic retinoPatHy aMong PatientS witH tyPe 2 diabeteS, 
HyPertenSion, and HyPerliPideMia
Han Y, Balkrishnan R, Thompson DA, Richards JE, Stein JD
University of Michigan, Ann Arbor, MI, USA
The progression from Non-Proliferative Diabetic Retinopathy (NPDR) to Proliferative 
Diabetic Retinopathy (PDR) is associated with a decline in best-corrected visual 
acuity and related health care utilization. Few studies have systematically assessed 
the effect of pharmacological regimens in delaying the progression of PDR.  Many 
patients are also on chronic medication regimens which may also have tempo-
ral effects on the risk of disease progression.objeCtives: Examine how patients’ 
chronic medication utilization potentially influences their PDR progression among 
NPDR patients with type-2 diabetes, hypertension and hyperlipidemia in the 
United States. Methods: This retrospective cohort study was conducted using 
a claims database of all beneficiaries had any ophthalmic care and were enrolled 
in a large managed-care network from 2001 to 2012. Utilization of distinct oral 
hypoglycemic agents, blood pressure lowering agents and lipid lowering agents 
were measured by the total cumulative dosage of medication (g) within a three 
year moving window. A multivariate Cox regression analysis with medication use 
as a time-varying covariate assessed the association between medication use and 
progression to PDR. Results: A total of 10,845 NPDR patients with all of these 
three conditions were eligible for this study, and 837(7.72%) of them developed PDR 
during the follow up period. Increased use of Statins was associated with a signifi-
cant decreased hazard of developing PDR (Hazard Ratio: 0.995 95%CI [0.99–0.999], 
p< 0.05) after adjusting for demographic and clinical confounders. Patients with 
increased use of insulin had increased hazard of developing PDR (Hazard Ratio: 
1.002 95%CI [1.001-1.004], p< 0.01). Potential risk factors of PDR progression included 
HbA1c level and diabetes-related complications. ConClusions: By developing a 
time-dependent medication use model, our study provides important information 
on physicians’ prescribing strategies aimed at preventing PDR progression among 
patients with type-2 diabetes, hypertension and hyperlipidemia. Increasing adher-
ence to statins for patients diagnosed with all of these three components of meta-
bolic syndrome may be helpful for delaying their PDR progression.
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objeCtives: To evaluate the impact of the use of guideline recommended care 
on the risk of subsequent moderate to severe COPD exacerbation requiring hospi-
talization or emergency department (ED) visit following discharge from COPD in a 
privately insured population in Texas. Methods: Retrospective population-based 
cohort study design using Blue Cross Blue Shield of Texas (BCBSTX) enrollment and 
claims data (years 2008 to 2011) was employed. All COPD-related hospitalizations 
and ED visits were extracted. Patients were identified as adherence to guideline 
recommended care if within 30 days of discharge, had at least one claim of pre-
scription fills for any maintenance medications and had at least one follow up visit 
with a primary care physician or pulmonologist. The presence of a subsequent 
COPD-related exacerbation requiring hospitalization or an ED visit was assessed for 
